Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England

Objective: To investigate whether an association between the use of selecti ve serotonin reuptake inhibitor (SSRI) antidepressants and abnormal bleedin g is demonstrated in a large population study. Methods: An observational cohort study using cohorts from the Drug Safety R esearch Unit's prescription event monitoring database was performed. Results: Analysis of combined haemorrhagic event rates calculated for the f irst 6 months of treatment for four SSRIs showed no significant difference between the rate for abnormal bleeding in the first month after starting tr eatment compared with months 2-6 [difference in rates 0.63 per 1000 patient months of treatment, 99% confidence interval (CI) -0.4, 1.67]. Comparison of the rates for the exposed combined SSRI cohort with the unexposed non-ps ychiatric drug cohort for the first month [relative risk (RR) 1.38, 95%CI 0 .82, 2.34] and months 2-6 (RR 1.17, 95%CI 0.81, 1.68) showed no significant differences after adjustment for age and gender. However, there was a tend ency towards highest risk with the combined SSRI cohort and lowest with the baseline cohort. Conclusion: This study provides weak evidence to support the hypothesis of a link between SSRIs and precipitation of bleeding events at a population l evel. The 95% CI is consistent with a possible risk of bleeding associated with SSRI users versus non-psychiatric drug users in the first month. Fulle r consideration of confounding would be possible using follow-up of identif ied cases in a nested case-control study.